Sprengerinin CCAS# 88861-91-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 88861-91-0 | SDF | Download SDF |
PubChem ID | 44583957 | Appearance | Powder |
Formula | C44H70O16 | M.Wt | 855.0 |
Type of Compound | Steroids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-4-hydroxy-6-(hydroxymethyl)-2-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol | ||
SMILES | CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(CO8)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1 | ||
Standard InChIKey | HSOMTBUZSIVDQK-QYOOOATOSA-N | ||
Standard InChI | InChI=1S/C44H70O16/c1-19-8-13-44(54-17-19)20(2)30-28(60-44)15-26-24-7-6-22-14-23(9-11-42(22,4)25(24)10-12-43(26,30)5)56-41-38(59-40-35(51)33(49)31(47)21(3)55-40)36(52)37(29(16-45)57-41)58-39-34(50)32(48)27(46)18-53-39/h6,19-21,23-41,45-52H,7-18H2,1-5H3/t19-,20+,21+,23+,24-,25+,26+,27-,28+,29-,30+,31+,32+,33-,34-,35-,36+,37-,38-,39+,40+,41-,42+,43+,44-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Sprengerinin C can strongly suppress tumor angiogenesis in human umbilical vein endothelial cells, it blocks vascular endothelial growth factor receptor 2-dependent phosphoinositide 3-kinase/Akt/mTOR/matrix metalloproteinase and p38 MAPK/matrix metalloproteinase pathways,two major pathways for tumor angiogenesis; sprengerinin C also can induce HepG-2/BEL7402 cell apoptosis by activating NADPH oxidase/reactive oxygen species-dependent caspase apoptosis pathway and suppress HepG-2/BEL7402 cell growth through p53-mediated G2/M-phase arrest, suggests that sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis. |
Targets | VEGFR | p38MAPK | PI3K | mTOR | Akt | NADPH-oxidase | ROS | p53 |
Sprengerinin C Dilution Calculator
Sprengerinin C Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.1696 mL | 5.848 mL | 11.6959 mL | 23.3918 mL | 29.2398 mL |
5 mM | 0.2339 mL | 1.1696 mL | 2.3392 mL | 4.6784 mL | 5.848 mL |
10 mM | 0.117 mL | 0.5848 mL | 1.1696 mL | 2.3392 mL | 2.924 mL |
50 mM | 0.0234 mL | 0.117 mL | 0.2339 mL | 0.4678 mL | 0.5848 mL |
100 mM | 0.0117 mL | 0.0585 mL | 0.117 mL | 0.2339 mL | 0.2924 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 11,12-De(methylenedioxy)danuphylline
Catalog No.:BCN4436
CAS No.:888482-17-5
- Ganetespib (STA-9090)
Catalog No.:BCC2336
CAS No.:888216-25-9
- Galanin (porcine)
Catalog No.:BCC5960
CAS No.:88813-36-9
- Gambogoic acid B
Catalog No.:BCN7936
CAS No.:887923-50-4
- Isogambogenic acid
Catalog No.:BCN3076
CAS No.:887923-47-9
- Gaudichaudic acid
Catalog No.:BCN3071
CAS No.:887923-46-8
- Bafetinib (INNO-406)
Catalog No.:BCC4036
CAS No.:887650-05-7
- (-)-Holostyligone
Catalog No.:BCN2863
CAS No.:887501-28-2
- Fmoc-Arg(Mts)-OH
Catalog No.:BCC3075
CAS No.:88743-97-9
- INCB 3284 dimesylate
Catalog No.:BCC1646
CAS No.:887401-93-6
- 3,9-Dihydroeucomin
Catalog No.:BCN6832
CAS No.:887375-68-0
- K-115
Catalog No.:BCC5500
CAS No.:887375-67-9
- Adrenorphin, Free Acid
Catalog No.:BCC1011
CAS No.:88866-92-6
- Sprengerinin A
Catalog No.:BCN6658
CAS No.:88866-99-3
- Fosinopril sodium
Catalog No.:BCC2141
CAS No.:88889-14-9
- Inulanolide A
Catalog No.:BCN3705
CAS No.:888941-86-4
- Atrial natriuretic factor (1-28) (rat)
Catalog No.:BCC5843
CAS No.:88898-17-3
- Bafilomycin A1
Catalog No.:BCC3914
CAS No.:88899-55-2
- Mogroside V
Catalog No.:BCN1036
CAS No.:88901-36-4
- Mogroside IIIe
Catalog No.:BCN7924
CAS No.:88901-37-5
- Mogroside IIe
Catalog No.:BCN3168
CAS No.:88901-38-6
- Mogroside IVa
Catalog No.:BCN3165
CAS No.:88901-41-1
- Mogroside III-A1
Catalog No.:BCN3170
CAS No.:88901-42-2
- Mogroside III-A2
Catalog No.:BCN7925
CAS No.:88901-43-3
Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.[Pubmed:23684542]
Eur J Pharmacol. 2013 Aug 15;714(1-3):261-73.
The multi-targeted therapy for liver cancer has been considered as a novel strategy to fight hepatocellular carcinoma. In this study, we first found that Sprengerinin C, a naturally derived compound strongly suppressed tumor angiogenesis in human umbilical vein endothelial cells. A mechanism study revealed that Sprengerinin C blocked vascular endothelial growth factor receptor 2-dependent phosphoinositide 3-kinase/Akt/mTOR/matrix metalloproteinase and p38 MAPK/matrix metalloproteinase pathways, two major pathways for tumor angiogenesis. Moreover, Sprengerinin C inhibited vascular endothelial growth factor release, a vital event for early angiogenesis response, from hypoxic HepG-2/BEL7402 cells by suppressing hypoxia-inducible factor-1alpha transcriptional activity. Furthermore, Sprengerinin C induced HepG-2/BEL7402 cell apoptosis by activating NADPH oxidase/reactive oxygen species-dependent caspase apoptosis pathway and suppressed HepG-2/BEL7402 cell growth through p53-mediated G2/M-phase arrest. Sprengerinin C also showed a significant anti-tumor effect in the nude mouse xenograft model of human hepatocellular carcinoma. These results provide new insights into development of potent candidate compounds for liver cancer through affecting multiple tumor progression steps of angiogenesis, apoptosis and proliferation.